The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 2.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (5 analysts) rates it none, with a mean price target of $7.
Companhia de Saneamento Basico do Estado de Sao Paulo ADR
SBS · the NYSE · USD · Market cap $17.0B · 8,927 employees
Companhia de Saneamento Básico do Estado de São Paulo - SABESP provides basic and environmental sanitation services in the São Paulo State, Brazil.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price4.92 USD at the 13 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 13 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.03)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $5.22 to $7.58, base estimate $6.23 (screen dated 2026-11-13).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.03, read 2026-11-13
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Companhia de Saneamento Basico do Estado de Sao Paulo ADR holds its Distribution at $4.92. The statistical read favours the buyers, held for 9 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the buyers, held for 9 days |
| Price at the screen | $4.92 |
| Valuation | 10.93 trailing · 11.91 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.12 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 38.52% | Below 33% | Interest-bearing debt is 38.5% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 20.79% | Below 33% | Cash held in interest-bearing accounts and securities is 20.8% of assets, under the one-third limit. | Pass |
| Receivables | 8.71% | Below 49% | Money owed to the company is 8.7% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.50% | Below 5% | Only 1.5% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Companhia de Saneamento Basico do Estado de Sao Paulo's business is in a permissible area, but its interest-bearing debt is about 39% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SBS's ethical verdict changes
Today SBS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 21% discount to our $6.23 fair value, narrow competitive moat, 13.90% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 21.0% discount to the base estimate.
Third-party analyst targets: 6 covering, consensus Strong Buy. The average target sits +30% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $6.23, with a range of $5.22 to $7.58, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsSao Paulo Taps Look Cheap But We Pass
When a Sao Paulo household turns on the tap the water still has to come from somewhere. SABESP runs the pipes and sewage plants across the state and the numbers look tidy. Revenue growth sits at 18 percent with a 22 percent profit margin and 21 percent ROE yet the opportunity rating stays at none.
A forward multiple of 10.4 times and a 31 percent gap to our fair value of 7.55 dollars would normally catch the eye. The narrow moat and clean ethical screen add to the case on paper. Still the business sits inside a single emerging market state where regulation and politics can shift the returns faster than the numbers suggest.
Currency moves and local political risk remain the real variables here. A regulated water utility rarely escapes those pressures even when the reported margins look solid. Analysis, not advice.
| Forward P/E | 11.9xfairly priced for its growth rate |
| Trailing P/E | 10.9xreasonably valued |
| EPS, trailing | 0.44 |
| EPS, forward | 0.40 |
| Revenue growth | +13.9%steady growth |
| Profit margin | 19.7%healthy profit margins |
| Return on equity | 18.8%a solid return on shareholder capital |
| FCF yield | -36.91% |
| Dividend yield | 0.64% |
| Debt to equity | 1.14a meaningful debt load worth watching |
| Current ratio | 1.47adequate liquidity, worth monitoring |
| Beta | 0.12barely tracks the market's swings |
| Short interest, float | 0.01% |
| 52-week range | 4.34 - 7.16 |
| Moat | NARROW |
| Market cap | $17.0B |
| Employees | 8,927 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Brazil and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeSBS trades on the NYSE (the company is based in Brazil). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 5.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (5 analysts) rates it none, with a mean price target of $7.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 29.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (5 analysts) rates it none, with a mean price target of $7. Since the last review it its composite score rose.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (5 analysts) rates it none, with a mean price target of $7.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (5 analysts) rates it none, with a mean price target of $7.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 24.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (5 analysts) rates it none, with a mean price target of $7. Since the last review it its composite score eased.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (5 analysts) rates it none, with a mean price target of $7. Since the last review it its composite score eased.
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 7.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (5 analysts) rates it none, with a mean price target of $7.
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (5 analysts) rates it none, with a mean price target of $7.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (5 analysts) rates it none, with a mean price target of $7.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Stratec SE (XTER:SBS) Q3 2026 Earnings Call Highlights: Margin Expansion and Diatron ... Yahoo Finance · 3d ago
- Stratec Q3 Earnings Call Highlights Yahoo Finance · 3d ago
- What Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp (SBS) Said on Its Q3 Earnings Call Yahoo Finance · 8d ago
- Companhia De Saneamento Basico Do Estado De Sao Paulo (SBS) Q3 2026 Earnings Call Highlights: ... Yahoo Finance · 9d ago
- Sabesp: Q3 Earnings Snapshot Yahoo Finance · 10d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $6.26 | -14.5% | · | $855 | -14.5% |
| 2 months | $6.82 | -21.5% | · | $785 | -21.5% |
| 3 months | $5.46 | -2.0% | $0.03 | $986 | -1.4% |
| 6 months | $4.92 | +8.9% | $0.03 | $1,095 | +9.5% |
| 1 year | $4.10 | +30.6% | $0.03 | $1,313 | +31.3% |
| 2 years | $2.70 | +98.7% | $0.16 | $2,047 | +104.7% |
| 3 years | $2.11 | +153.7% | $0.22 | $2,641 | +164.1% |
| 5 years | $1.40 | +283.7% | $0.31 | $4,059 | +305.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever SBS does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.